Amprenavir Vertex Pharmaceuticals Inc

IDrugs

Volumn 2, Issue 5, 1999, Pages 466-482

  Billich, Andreas ^a  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR;

ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SOLUBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PROTEINASE INHIBITION; REVIEW; VIRUS INHIBITION;

EID: 0032895553     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (278)

1. 158773 Vertex Pharmaceutical Inc ANNUAL REPORT 1993
2. 174455 HIV protease Inhibitors show increasing promise CHEM ENG NEWS 1995 73 February 6 7
3. 158773 Vertex Pharmaceutical Inc ANNUAL REPORT'1993
4. 158775 Wellcome/Vertex link on AIDS SCRIP 1993 1814 15
5. 158776 Wellcome/Vertex HIV Protease Inhibitor R&D Collaboration FDC REPORTS PINK SHEET 1993 55 Dec 20 T&G-13
6. 158783 Anti-infective Drugs DRUG NEWS PERSPECT1994 7 2 107
7. 158881 Vertex Product Development Status DRUG NEWS PERSPECT 1994 7 2 118
8. 159644 Vertex and Wellcome sign $42 million agreement to develop novel drugs to treat HIV infection and AIDS Vertex PRESS RELEASE 1993 December 161-2
9. 159782 Design and optimization of potent, orally active HIV aspartyl protease inhibitors Tung RD, Livingston DJ, Rao GB, Kim EE, Pazhanisamy S, Deininger DD, Murcko MA INT CONF AIDS 199410th Yokohama Abs C2
10. 161085 Other protease inhibitors SCRIP 1994 1953 21
11. 161518 Welcome's five AIDS drugs In R&D SCRIP 1994 1954/55 30 This article discusses the five compounds that Wellcome (then) had in development against HIV. 524W91 was one of three which were active as reverse transcriptase inhibitors.
12. 167498 Vertex and Kissei pharmaceutical sign $20 million agreement to develop novel drugs to treat HIV Infection and AIDS Vertex Pharmaceuticals Inc PRESS RELEASE 1993 April 13 169283 Burroughs-Wellcome to file IND for Vertex protease inhibitor in December FDC REPORTS PINK SHEET 1994 56 49 T&G-8
13. 169626 IND filings soon for Vertex' HIV drug SCRIP 1994 1983 30
14. 170247 Vertex Pharmaceuticals Inc ANNUAL REPORT 1993 An introductory reference (annual report of the firm and oral presentation at the Second World Congress of Inflammation) reviewing Vertex's ICE inhibition program and the development of the evaluated compound.
15. 173081 Vertex COMPANY NEWSLETTER 1995
16. 174122 Vertex VX-478 enters Phase I SCRIP 1995 2005 25
17. 174826 Drug firms need biotech drug discovery BIOTECHNOLOGY 1995 13 March 208
18. 174892 Clinical trials to begin on designed AIDS drug Borman S CHEM ENG NEWS 1995 73 Feb 13 39-40
19. 175205 Orphan drugs designated in Japan SCRIP 1995 2014 25
20. 175966 Vertex Pharmaceutical Inc ANNUAL REPORT 1994
21. 177097 Kissei Pharmaceutical Co. Begins Clinical Trial Program In Japan with Vertex Pharmaceuticals' HIV Protease Inhibitor Vertex Pharmaceuticals Inc PRESS RELEASE 1995 April 26
22. 177119 Vertex Pharmaceuticals Inc FORM IO-K1994 December 31
23. 177694 Burroughs Wellcome Co Begins US Clinical Trial Program with Vertex Pharmaceuticals' Protease Inhibitor for HIV Vertex Pharmaceuticals Incorporated PRESS RELEASE 1995 February 28
24. 178133 Vertex reports on1994 SCRIP 1995 2028 17
25. 178316 Kissei/Vertex' KVX-478 enters Japan trials SCRIP 1995 2029 18
26. 179949 Vertex Pharmaceuticals Inc 1ST QUARTER REPORT 1995 March 31
27. 180800 Roche Invirase resistance not evident in 50% of patients at one year FDC REPORTS PINK SHEET 1995 57 29 T&G-4
28. 181770 Vertex Pharmaceuticals reports 1995 second quarter and six month results Vertex Pharmaceuticals Incorporated PRESS RELEASE 1995 July 26
29. 181782 Preliminary Phase 1 data reported on Vertex/Glaxo Wellcome HIV protease inhibitor Vertex Pharmaceuticals Incorporated PRESS RELEASE 1995 July 26
30. 182360 Advances with protease inhibitors SCRIP 1995 2048 21
31. 183705 VX-478 Kissei Pharmaceutical Co Ltd CLIN TRIALS MONITOR 1995 4 6 P15
32. 186869 HIV protease inhibitors head to market Stone D BIOTECHNOLOGY 1995 13 9 940-942 Review of the market potential of the leading HIV-protease inhibitor drugs.
33. 189466 Structural analysis of the basis of viral resistance to VX-478. Kim EE, Dwyer MD, Thomson JA, Baker CT. Deininger DD, Tung RD. Navia MA, Rao BG ICAAC1995 35th San Francisco Abs I278
34. 192678 Glaxo Welcome's R&D challenge SCRIP 1995 2080 8-9
35. 193105 Glaxo Wellcome to Increase R&D productivity three-fold by the year 2000 Glaxo Wellcome pic PRESS RELEASE 1995 November 8 Attached to this press release is a supplement entitled 'Glaxo Wellcome compounds in development November 1995' containing the company's drug development portfolio.
36. 194446 Glaxo Wellcome begins phase l/ll clinical trials with Vertex pharmaceuticals protease inhibitor for HIV. Vertex Pharmaceuticals Inc PRESS RELEASE 1995 December 14
37. 194908 Progress with Vertex1 protease inhibitor SCRIP 1996 2090/2091 25
38. 195065 Hambrecht & Quist Health Care Conference - San Francisco January 1996 HAMBRECHT & QUIST 1996 January 7-10
39. 195460 Vertex earns $5.0 million in milestone payments from Glaxo Wellcome and Kissei Vertex Pharmaceuticals Inc PRESS RELEASE 1996 January 8
40. 197288 Vertex payments from Glaxo Wellcome and Kissei SCRIP 1996 2098 10
41. 197434 VX-478 (141W94) CL W TRIALS MONITOR 1996 5 1 P10 16309 Phase l/ll trial dose ranging study in 10 patients.
42. 197805 Data sheets for collection of developmental drugs. Glaxo Wellcome pic COMPANY BROCHURE 1996 February 5
43. 200045 Recent advances in HIV-1 protease inhibitors. Chong XT EXP OPIN INVEST DRUGS 1996 5 1 115-124 A review, with the prognosis for HIV-1 protease inhibitors.
44. 200103 Japan CTs for JT/Agouron HIV drug SCRIP 1996 2105 25
45. 200280 Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: A paradigm for the cure of AIDS? De Clercq E, Balzarini J FARMAC01995 50 11 735-747
46. 202114 In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors if HIV-1 aspartyl protease. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, et al J VIROL 1995 69 9 5228-5235 Paper on the occurrence of amprenavir-resistant virus.
47. 202115 Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED ANTIMICROB AGENTS CHEMOTHER 1995 39 8 1704-1710
48. 202117 Expedient method for the solid-phase synthesis of aspartic acid protease inhibitors directed toward the generation of libraries. Kick EK, Ellman JA J MED CHEM 1995 38 9 1427-1430
49. 202122 Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. Livington DJ, Pazhanisamy S, Porter DJ, Partaledis JA, Tung RD, Painter GR J INFECT DIS 1995 172 5 1238-1245
50. 202124 Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD, Navia MA JAM CHEM SOC1995 1173 1181-1182 A paper showing the crystal structure of HIV-1 protease complexed with amprenavir, along with enzyme, antiviral and solubility data of the compound.
51. 202127 In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivprakash M, Titus D, et al NATURE 1995 374 6522 569-571
52. 202133 An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94). Painter GR, StClair MH, Demiranda P, Reynolds D, Cning S, Domsife R, Livingston DJ, Pazhanisamy S, Tung R AM SOC MICROBIOL HUM RETROVIRUSES RELAT INFECT1995 Washington, DC 167
53. 202135 Design of VX-478, a potent inhibitor of HIV protease. Navia MA, Sato VL, Tung RD INT ANTIVIRAL NEWS 1995 3 9 143-145 A detailed description of the design of amprenavir.
54. 203336 Xth International Conference on AIDS: Yokohama, Japan, 7-12 August 1994. Stein C INT ANTIVIRAL NEWS 1994 2 9 138-139
55. 203725 Present status of HIV protease inhibitors in the control of HIV infections. Naesens L, De CLERCQE EXP OPIN INVEST DRUGS 1996 5 2 153-154
56. 203748 Rationale and experience with reverse transcriptase inhibitors and protease Inhibitors. Vella S J ACQUIRED IMMUNE DEFIC SYNDR HUM RETROVIROL 1995 10 Suppl 1 S58-S61
57. 204363 Vertex Pharmaceuticals appoints Bart Henderson Director of Marketing. Vertex Pharmaceuticals Inc PRESS RELEASE 1996 April 2
58. 206065 Current status of the development of HIV protease inhibitors and their clinical potential. Ueno T, Mitsuya H CLIN IMMUNOTHER1995 4 6 451-461 A review, with the prognosis forHIV-1 protease inhibitors.
59. 212664 Glaxo Wellcome invests $5 million in Vertex Glaxo Wellcome and Vertex obtain license to GD Searle patent applications Glaxo Wellcome pic PRESS RELEASE'1996 July 1
60. 213844 Ninth International Conference on Antiviral Research. Vertex Pharmaceuticals Inc PRESS RELEASE 1996 May 23
61. 213917 Searle to license out HIV patents SCRIP 1996 2146 9
62. 213921 [In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors]. IN-VIVO-ENTWICKLUNG VON HIV-1-VARIANTEN MIT EINER RESISTENZ GEGENUBER MULTIPLEN PROTEASE-INHIBITOREN. Luke W AIDS FORSCHUNG 1996 11 4 181-183
63. 213965 GW/Vertex license Searle patents SCRIP 1996 2144 9
64. 214719 Vertex to receive U.S. patent covering VX-478 to treat HIV infection and AIDS. Vertex Pharmaceuticals Inc PRESS RELEASE 1996 July 24
65. 214928 Vertex Pharmaceuticals Inc ANNUAL REPORT 1995
66. 216007 Glaxo Wellcome, World Leader in HIV Therapy: Commitment to Research and Development. Glaxo Wellcome pic COMPANY BROCHURE 1996 J uly 7-12 Press information regarding Glaxo Wellcome's antiretroviral compounds, given out at the Xlth International Conference on AIDS
67. 216320 Second International Symposium: Recent Advances in the Chemistry of Anti-Infective Agents Churchill College, Cambridge, 7-10 July 1996 IDDB MEETING REPORT 1996 July 7-10
68. 216892 Vertex nets nearly S70M in public offering BIOWORLD TOQ4V199671561-2
69. 217569 HIV protease inhibitors in early development. Sham H, Chen X EXP OPIN INVEST DRUGS 1996 5 8 977-983 A review, with the prognosis forHIV-1 protease inhibitors.
70. 218850 3TC, Largest Selling HIV Drug, Patent Infringement Suit ANTIVIRAL AGENTS BULL 1996 Aug 1
71. 219555 AIDS Clinical Trial Group (ACTG) to conduct clinical study of 141W94/VX-478, an HIV protease inhibitor Vertex Pharmaceuticals Inc PRESS RELEASE 1996 September 12
72. 219582 141W94. Anti-HIV. Painter GR, Ching S, Reynolds D, StClair M, Sadler BM, Elkins M, Blum R, Domsife R, IJvingston DJ, Partadelis JA, et al DRUGS FUTURE 1996 21 4 347-350 A review of amprenavir written by researchers from Vertex and Glaxo Wellcome.
73. 219667 Phase l/ll clinical data reported on Glaxo Wellcome/Vertex HIV protease inhibitor Vertex Pharmaceuticals Inc PRESS RELEASE 1996 September 16
74. 220178 AIDS conference highlights hope of drug cocktails, chemokine research Wilson EK CHEM ENG NEWS 1996 74 31 42-46
75. 220240 36th ICAAC, New Orleans September 15-18 IDDB MEETING REPORT 1996 September, 15-18 Describes in vitro inhibition data for pentafuside (T-20; ECy, = 80 ng/ml), an in vivo study of SCID mice, and shows the half-life to be 2.4 h in rodents. Also describes results of a phase II trial of pleconaril in volunteers at 400 mg prior to infection and 200 mg tid for the next 6 days.
76. 220647 Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. Pazhanisamy S, Stuver CM, Cullinan AB, Margolin N, Rao BG, Livingston DJ J BIOL CHEM 19962713017979-17985
77. 220649 Structure-based drug design of HIV protease inhibitors. Navia MA, Tung RD, Chaturvedi PR, Rao BG, Partaledis JA, Kim EE FASEB J1996 10 6 A1422
78. 220653 Selection for protease inhibitors using bacteriophage display. Markland W, Roberts BL, Ladner RC METHODS ENZYMOL 1996 267 28-51
79. 220654 Calculation of solvation and binding free energy differences between VX-478 and its analogs by free energy perturbation and AMSOL methods. Rao BG, Kirn EE, Murcko MA J COMPUT AIDED MOL DES 1996 10 1 23-30
80. 220784 Effect of a-1-acid glycoprotein on CGP-61755. An in vitro comparative study with other relevant HIV protease inhibitors. Lazdins JK ICAAC 1996 36th New Orleans Abs 17
81. 220797 New Data On Anti-HIV Drugs Presented MARKETLETTER1996 Sep 30
82. 221186 In Brief FDC REPORTS PINK SHEET 1996 58 29 T&G-19T&G-20
83. 221326 Kissei starts phase II study on anti-aids drugs in the US PHARMA JPN1996 1519 1 -2
84. 221449 Agouron Pharmaceutical Inc ANNUAL REPORT 1996 October
85. 221999 Glaxo / Vertex HIV protease inhibitor 141W94 shows 99% reduction in viral load FDC REPORTS PINK SHEET 1996 58 39T&G-10-T&G-11
86. 222233 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: Antivirals IDDB MEETING REPORT 1996 September 15-16 An abstract showing effectiveness of pleconaril against 215 clinical isolates of enteroviruses.
87. 222305 Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease [letter; comment]. Bilello JA, Drusano GL J INFECT DIS 1996 173 6 1524-1526
88. 222307 In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. Singh R, Chang SY, Taylor LCE RAPID COMMUN MASS SPECTRUM 1996 10 9 1019-1026
89. 222308 Current knowledge and future prospects for the use of HIV protease Inhibitors. Moyle G, Gazzard B DRUGS 1996 51 5 701-712
90. 222309 Structural mechanisms of HIV drug resistance. Erickson JW, Burt SK ANNU REVPHARMACOL TOXICOL 1996 36 545-571
91. 222310 Antiretroviral drug resistance: Mechanisms, pathogenesis, clinical significance. Richman DD ADV EXP MED BIOL 1996 394 383-395
92. 222311 New initiatives in combination antiretroviral chemotherapy. Rooney JF, Warwick JC, Elkins MM, St CLAIRMH, Bany DW ADV EXP MED BIOL 1996 394 373-382
93. 222313 In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. StClair MH, Millard J, Rooney J, Tlsdale M. Parry N, Sadler BM, Slum MR, Painter G ANTIVIRAL RES 199629153-56 141W94, an HIV protease inhibitor from Vertex, can be used in combination with 524W91, a reverse transcriptase inhibitor, to treat HIV infections. This paper provides an overview on the antiviral activity of amprenavir, including viral resistance and protein binding.
94. 222314 A clinical study of the HIV-1 protease inhibitor, 141W94 (VX-478) to evaluate a new soft gelatin capsule formulation and to determine the effects of food upon bioavailability. Symonds WT, Sadler BM, Chittick GE, Moss J ANTIVIRAL RES 1996 301 A42
95. 222316 Pharmacokinetics of 141W94 after multiple dosing in patients with HIV infection: A preliminary report Sadler BM, Rawts C, Millard J, Hanson C, Dowd P ANTIVIRAL RES 1996 301 A42
96. 222317 Consensus symposium on combined antiviral therapy. De JONGMD, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD ANTIVIRAL RES 1996 29 1 5-29
97. 222318 Antiretroviral chemotherapy against AIDS. Maeda Y, Mitsuya H MED BIOL ENVIRON 1995 23 2 267-278
98. 222319 In vitro studies support combination therapy with HIV protease inhibitors. Tisdale M, Myers RE, Blair E, Kohli A, Kemp SD, Larder BA J ACQUIRED IMMUNE DEFIC SYNDR HUM RETROVIROL 199510 Suppl. 3 S30-S31
99. 222328 Design and optimization of potent orally active HIV aspartyl protease inhibitors Tung RG, Livingston DL, Rao GB, Kim E, Pazhanisamy S, Deininger DD INTCONFAIDS1994 10th Yokohama 33
100. 222463 New Drug Development in HIV Disease: Advances in treatment strategies BHK Communications Ltd & Publishing Solutions IDDB MEETING REPORT 1996October 12-13 This meeting report shows the importance of viral load monitoring and compares tfie effectiveness of several treatment regimens, including Loviride.
101. 222532 Vertex Pharmaceuticals researchers report threedimensional structure of hepatitis C protease enzyme; Report in cell Vertex designing new treatments for hepatitis C infection Vertex Pharmaceuticals PRESS RELEASE 1996 October 18
102. 222742 VX-478 (141W94VRetrovir (AZTVEpivir (3TC) Glaxo Wellcome pic CUN TRIALS MONITOR 1996 5 10 Ab 19280
103. 225995 Protease Inhibitors: New Therapeutics and Approaches IDDB MEETING REPORT 1996 November 6-7
104. 226596 Clinical trial update: September 1996 BIOWORLD FINANCIAL WATCH 1996 4 44 7-10
105. 226713 Drug development pipeline DRUG DEV PIPELINE19961 61
106. 227964 Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV-infected patients with 1150-400 CD4+ cells/mmS. Schooley R, et al ICAAC 1996 36th New Orleans AbsLB7a
107. 229504 Glaxo Wellcome begins phase II clinical trial of 141W94/VX-478 in double HIV protease inhibitor treatment regimen Vertex Pharmaceutical Inc PRESS RELEASE 1997 January 9
108. 229646 Advances In antiretroviral therapy and viral load monitoring. Hammer SMAIDS199610 3 S1-S11
109. 229653 Anti-HIV chemotherapy: Quo vadis? De Clercq E INT ANTIVIRAL NEWS 1996 4 7126 A review, with the prognosis forHIV-1 protease inhibitors.
110. 229726 Use of viral resistance patterns to antiretroviral drugs in optimizing selection of drug combinations and sequences. Moyle GJ DRUGS 1996 52 2 168-185
111. 230242 Vertex lead immunosuppressive SCRIP 1996 2189 21
112. 230289 Glaxo Wellcome Compounds in Development COMPANY BROCHURE 1996 December Glaxo Wellcome products in active development
113. 231407 Early results suggest potential for new combination of investigational anti-HIV drugs Vertex Inc , Glaxo-Wellcome PRESS RELEASE 1997 January 27
114. 231488 Vertex Pharmaceuticals: Resistance does not develop to HIV protease inhibitor 141W94/VX-478 in four-week clinical study Vertex Pharmaceuticals Inc PRESS RELEASE 1997 January 27
115. 232685 The 2nd Winter Conference on Medicinal and Bioorganic Chemistry Steamboat Springs, Colorado, USA IDDB MEETING REPORT 1997 January 26-31
116. 233439 A pharmacodynamic evaluation of ciprofloxacin and ofloxazin against two strains of Pseudomonas aeruginosa. Madaras-Keliy KJ, Larsson AJ, Rotschafer JC J ANTIMICROB CHEMOTHER1996 37 4 703
117. 234041 AIDS Clinical Trial Group (ACTG) begins clinical study of 141W94/VX-478, and HIV protease inhibitor Vertex Pharmaceuticals Inc PRESS RELEASE 1997 February 13
118. 234376 Formulations containing ritonavir and HIV protease inhibitor Abbott Labs WORLD PATENT 1997 1-29 Patent filed: 28JUN-96
119. 234788 Phase III Pivotal Clinical Trial Begins with 141W94/VX-478, a Protease Inhibitor Designed by Vertex for Treatment of HIV Infection and AIDS Vertex Pharmaceuticals Inc PRESS RELEASE 1997 February 19
120. 235330 Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. Maschera B, Darby G, Palu G, Wright U_ Tisdale M, Myers R, Blair ED, Furfine ES J BIOL CHEM1996 271 52 33231-33235
121. 235336 Ritonavir. Lea AP, Faulds D DRUGS 1996 52 4 541-6;
122. discussion 547-8
123. 236193 GWs double protease inhibitor trial SCRIP 1997 2198 19
124. 236197 IBC's 2nd International Conference on Protease Inhibitors: Novel Therapeutic Applications and Development, Washington DC, USA IDDB MEETING REPORT 1997 February 24-26
125. 236901 Agouron's positive Viracept trials SCRIP 1997 2202 16
126. 237782 Synthesis and SAR of a novel series of HIV aspartyl protease inhibitors Salituro FG, Baker CT, Court JT, Deininger DD. Kim B, Li B, Novak PM, Rao BG, Pazhanisamy S, Schairer WC, Tung RD WINTER CONF MED BIOORGANIC CHEM 1997 2nd
127. 238650 Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV Jadhav PK, Ala P. Woemer FJ, Chang CH, Garber SS, Anton ED, Bacheler LT J MED CHEM 1997 40 2 181-191
128. 239307 Vertex Pharmaceuticals1 offering soars to $136 million BIOWORLD WEEK 1997 5 11 1
129. 240163 GlaxoWellcome Annual Review 1996, Annual Report and Accounts 1996, Form 20-F 1996. Glaxo Wellcome pic ANNUAL REPORT 1997 March Includes the Glaxo Wellcome product development pipeline as at December 1996.
130. 24310910th International Conference on Antiviral Research (Part I) IDDB MEETING REPORT 1997 April 6-11
131. 243271 Vertex Pharmaceuticals reports first quarter 1997 results Vertex Pharmaceuticals Inc PRESS RELEASE 1997 April 22
132. 244813 Glaxo Wellcome compounds in development May 1997 COMPANY BROCHURE 1997 May Glaxo Wellcome's ding development portfolio.
133. 245667 A development portfolio for short and long term growth. Glaxo Wellcome pic COMPANY COMMUNICATION 1997 May 9
134. 246856 Glaxo Wellcome champions "breadth & depth11 of its R&D SCRIP 1997 2231 26
135. 247462 Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Kempf DJ, Marsh KG, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, et al ANTIMICROB AGENTS CHEMOTHER1997 41 3 654-660
136. 248334 Vertex Pharmaceuticals Inc ANNUAL REPORT 1996 December 31
137. 249985 Kissel develops new AIDS drug synthesis route SCRIP 1997222824
138. 250385 Famvir for herpes prevention in UK SCRIP 1997 2234 20
139. 251332 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Domsife RE, Averett DR, Krenitsky TA ANTIMICROB AGENTS CHEMOTHER 1997 41 5 1082-1093 Describes antiviral activity of carbovir and several of its analogs with emphasis on the unique biological profile of anti-HIV activity of carbovir.
140. 251815 rjritherapies in HIV infection: Prospects]. LES TRITHERAPIES DANS L'INFECTION VIH: ESPOIRS ET LIMITES. Perrin L, Schockmel G, Yerty S MED HYG1997 55 2161 862-865
141. 252615 New medicines in development for AIDS: 1996 survey from the pharmaceutical research and manufacturers of America. PEDIATR AIDS HIV INFECT 1997 B 1 67-78
142. 254428 Vertex and Glaxo Wellcome announce pivotal phase III trial of HIV protease inhibitor 141W94 (VX-478) in pediatric patients Vertex Pharmaceuticals Inc PRESS RELEASE 1997 July 10
143. 255668 GWs pediatric protease inhibitor trial SCRIP 1997 2250 19
144. 259325 Half-year review 1997: Disease has no greater enemy than Glaxo Wellcome Glaxo Wellcome pic COMPANY BROCHURE 1997 June 30
145. 259601 Antiretroviral therapies in HIV-1 infection. Mom's Jones S, Moyle G, Easterbrook P J EXP OP1N INVEST DRUGS 1997 6 8 1049-1061 A general review on the clinical trials report of antiviral therapies in HIV infection.
146. 259721 Glaxo Wellcome hit by sterling in first half SCRIP 1997 22566
147. 262512 Alpha/BASF drop Vertex butyrate drug SCRIP 1997 2266 21
148. 263362 Kissei joins with Vertex on MAP kinase SCRIP 1997 226810
149. 264425 Vertex and Glaxo Wellcome begin third phase III pivotal trial with HIV protease inhibitor .141W94 (VX-478) Vertex Pharmaceuticals Inc PRESS RELEASE 1997 September 29
150. 265764 Glaxo Wellcome's lamivudine/zidovudine combination for HIV. SCRIP 1997 2273 20
151. 265973 Vertex Pharmaceuticals Reports Encouraging Preliminary Data from Phase II Clinical Study with HIV Protease Inhibitor 141W94 Vertex Pharmaceuticals Inc PRESS RELEASE 1997 October 13
152. 266443 Double protease inhibitors - new gold standard in HIV. SCRIP 1997 2274 18-19
153. 267389 Glaxo Wellcome's quadruple HIV therapy SCRIP 1997 2278 22
154. 267955 IBC's 2nd international conference on protease inhibitors: Novel therapeutic applications and development, Washington DC, USA, 24-26 February 1997. VanNoorden CJF ACTA HISTOCHEM1997 99 3 249-255
155. 269651 Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: How to prevent the problem?. De Clercq E INT JANTIMICROB AGENTS 1997 9 1 21-36
156. 270170 Product development pipeline November 1997 Glaxo Wellcome pic COMPANY PROSPECTUS 1997 November Document outlining Glaxo Wellcome's drug development portfolio.
157. 271539 Roche Fortovase inclusion in HHS AIDS guidelines may reduce cost of saquinavir In combination with norvir, treatment panel member suggests FDC REPORTS PINK SHEET 1997 59 497-8 Discussion of the economic'aspects of combination therapy.
158. 271748 Analyst Report 1997 BancAmerica Robertson Stephens ANALYST REPORT 1997
159. 271840 Glaxo Wellcome drops antibiotic in phase III SCRIP 19972291 21
160. 272840 Nonsymmetrically substituted cyclic urea HIV protease inhibitors. Wilkerson WW, Dax S, Cheatham WW J MED CHEM 199740254079-4088
161. 273428 Kissei to collaborate with Vertex for p38 MAP kinase PHARMA JPN1997 1566 10-11
162. 274635 Vertex Pharmaceuticals announces start of clinical trial with VX-497, a novel compound for autoimmune diseases Vertex Pharmaceuticals Inc PRESS RELEASE 1998 January 13
163. 275003 1997 good but not great for US biotech SCRIP 1998 22989
164. 275707 DRUG DEV PIPELINE 1997 2 11 1-4 Among the drugs reported in this publication are inhaled and iv formulations of TBC-1269 from Texas Biotech, which are in preclinical development and phase II testing respectively.
165. 276611 Investigations! anti-HIV compound Abacavir with HIV protease inhibitors, including Vertex's amprenavir, results in potent antiretroviral activity Glaxo Wellcome pic PRESS RELEASE 1998 February 2
166. 276655 Biochem Pharma 3TC follow-on will enter clinic in the first quarter FDC REPORTS PINK SHEET 1998 60 4 T&G-14-T&G-15
167. 277074 In vitro effect of α1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors Lazdins JK, Mestan J, Goutte G, Walker MR, Bold G. Capraro HG. Klimkait T J INFECT DIS 1997 175 5 1063-1070
168. 277116 Arch rivals give good product pipeline mix SCRIP 1998 23068
169. 277120 Vertex reports positive HIV protease inhibitor data BIOWORLD WEEK 1998 6 6 3
170. 277398 Double protease inhibitor regimens containing Vertex's HIV protease inhibitor, amprenavir, show promise: investlgational protease inhibitor amprenavir appears potent, well tolerated Vertex Pharmaceuticals Inc PRESS RELEASE 1998 February 2
171. 277568 Glaxo Wellcome acquires rights to novel drugs to treat HIV; portfolio of investigational AIDS drugs grows Glaxo Wellcome Inc PRESS RELEASE 1998 February 12
172. 277686 Rational drug design gives hope to HIV and AIDS patients Sansom S SCRIP MAGAZINE 1998 65 23-25
173. 277940 Not just protease inhibitors, says AIDS conference SCRIP 1997 2308 26
174. 278801 Recent developments in HIV protease inhibitor research. Chrusciel RA, Romines KR EXP OPIN THER PAT 1997 7 2111-121
175. 279863 Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy Kempf DJ, Sham HL, Marsh KG, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, Kati WM, et al J MED CHEM1998 41 4 602-617 Details of the design, structure, and properties of ritonavir, a first-generation protease inhibitor in clinical practice and a predecessor ofABT-378.
176. 281014 Design and synthesis of peptide-based VLA-4 antagonists lead to asthma drug candidates. LJn K C, Zimmerman CN, Castro A, Lee W C, Hammond CE, Ateeq HS, Hsiung SH, Chong LT, Liao Y, Almquist RG, Kalkunte S, Adams SA ACS 1997 213 1-3 MEDI 315
177. 281057 Pharmaceutical Industry: Global Model Book Highlights: Models for the US, Europe, Emerging Europe and Japan. Merrill Lynch ANALYST REPORT 1998
178. 281133 The role of combinations of HIV protease inhibitors in the management of persons with HIV infection Moyle G EXP OPIN INVEST DRUGS 1998 7 3 413-426 Overview of the use of combination therapy, including HIV protease inhibitors, in the management of AIDS.
179. 281316 In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxy-ethylamino sulfonamide inhibitors of HIV-1 aspartyl protease Parteledis JA, Yamaguchi K, Tlsdale M, et al J VIROL 1995 69 5228-5235
180. 283664 [Modern therapy of HIV infection and AIDS]. MODERNE THERAPIE VON HIV-INFEKTION UND AIDS. DTSCH APOTH ZTG 19971372556-60
181. 283665 [Optimism at the Munich AIDS days]. OPTIMISMUS BEI DEN MÜNCHNER AIDS-TAGEN. Gensthaler BM PHARM Z 1997 1423247-48+51
182. 283685 Antiviral briefs. AIDS PATIENT CARE STDS 1998 12 1 63-66
183. 285132 Clinically effective HIV-1 protease inhibitors. Vacca JP, Condra JH DRUG DISC TODAY 1997 2 261-272 Overview of rational development of the four therapeutically used HIV protease inhibitors saquinavir, ritonavir, indinavir and nelfinavir.
184. 285146 Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule. De Lucca GV, Erickson Viitanen S, Lam PYS DRUG DISC TODAY'1997 216-18 Overview of the rational development of cyclic ureas as HIV protease (PR) inhibitors. Features the capability of the cyclic urea PR inhibitors to displace a structural water in the active site ofHIVPR.
185. 286391 Pharmacokinetics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers. Sadler BM, Eron J, Wakeford J, Pagano G, Rawls C, McCrea J, Mazina K, Deutsch PJ ICAAC1997 37th Toronto A-56
186. 286404 Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 Woolley J, Studenberg S, Boehleert C, Bowers G, Sinhababu A, Adams P ICAAC 1997 37th Toronto A-60
187. 286413 Pharmacokinetic (PK) interaction between ketoconazole (KCZ) and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers. Polk RE, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Crouch M, Gouldin W, Lou Y, Rawls C, Bye A ICAAC 1997 37th Toronto A-61
188. 286414 Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV+ patients McDowell JA, Sadler BM, Millard J, Nunnally P, Mustafa N ICAAC 1997 37th Toronto A-62
189. 287458 Glaxo Wellcome makes satisfactory start to 1998 trading Glaxo Wellcome pic PRESS RELEASE 1998 May 18
190. 287622 Vertex prepares for first product to market SCRIP 1998 2331 16
191. 288386 Sterling takes GW's sales down 7% SCRIP 1998 2337 9
192. 288864 Vertex announces HIV protease inhibitor amprenavir shown in clinical trials to cross blood-brain barrier and penetrate to key viral reservoir. Vertex Pharmaceuticals Inc PRESS RELEASE 1998 June 5
193. 290251 Product development pipeline June 1998 Glaxo Wellcome pic COMPANY BROCHURE 1998 June
194. 290605 New data on Vertex and Glaxo Wellcome's amprenavir suggests possible role in Immune Recovery and unique resistance profile. Vertex Pharmaceuticals Inc PRESS RELEASE 1998 June 30
195. 290606 Vertex and Glaxo Wellcome announce combination of investigational drugs Ziagen and Agenerase may be potent, durable against HIV. Vertex Pharmaceuticals Inc PRESS RELEASE 1998 June 30
196. 291403 Vertex Pharmaceuticals provides update on portfolio of drugs in research and development at annual meeting of shareholders Vertex Pharmaceuticals Inc PRESS RELEASE 1998 May 27
197. 295602 Pharmaceutical and biotechnology bulletin Merrill Lynch ANALYST REPORT 1998 August
198. 295619 Resistance to antiretroviral therapy Molla A, Kohlbrenner WE ANN REP MEDICINAL CHEM, BRISTOL JA (ED) 1997 32 131 -140
199. 296496 A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues. Nair AC, Miertus S. Tossi A, Romeo D BIOCHEM BIOPHYS RES COMMUN 1998 242 3 545-551
200. 296497 [Antiretroviral agents in the pipeline]. ANTIRETROVIRALE GENEESMIDDELEN IN DE PU PLU N. Burger DM, Hoetelmans RMW, Koopmans PP, Hekster YA PHARM WEEKBL1998133 6 273-279
201. 296498 Aids dementia complex: Diagnosis and drug treatment options. Portegies P, Rosenberg NR CNS DRUGS 1998 9 1 31-40
202. 296499 Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Moyle GJ EXP OPIN INVEST DRUGS 1997 6 8 943-964
203. 296500 [Pharmacological treatment of AIDS]. TRATAMIENTO FARMACOLOGICO DEL SIDA. Villar VM, Dasi Femandez F, Cortijo Gimeno J, Leon Monzon M FARM CUN BARCELONA 1997 14 8 532-540
204. 296501 Preparation of (2S, 3S)-N-protected-3-amino-1,2-epoxy-4-phenylbutane: A key intermediate in hydroxyethylamine-based HIV protease inhibitor 141W94. Fugett MJF4CS1997 213 1-3 ORGN 456
205. 296502 Effects of 141W94 and clarithromycin (CLRY) on P450 (CYP) 3A4 activity as measured by the erythromycin breath test (ERMBT). Poik RE, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Lou Y, Richards L, Bye A CUN INFECT DIS 1997 25 2 399
206. 296503 Effects of the HIV-1 protease inhibitor, 141W94, and rifampin (RFM), and rifabutin (RFB) on P450 (CYP) 3A4 activity as measured by the erythromycin breath test (ERMBT). Polk RE, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Brophy DF, Kristoff D, Bye A CUN INFECT DIS 1997 25 2 399
207. 296504 Theoretical benefits of mitogen applications for HIV-1 Infections. Wimer BM, Morris RE CANCER BIOTHERAPY RADIOPHARMACEUTICALS199712 3 213-222
208. 296505 Piperazinylfluoroquinolines as inhibitors of HIV-1 transcription. Baba M INT ANTIVIRAL NEWS 1997 5 11 203-204
209. 296506 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Barry M, Gibbons S, Back D, Mulcahy F CUN PHARMACOKIN1997 32 3 194-209
210. 296507 Recent advances in HIV therapy. Slade P, Churchill D CARE CRITILL 199713 4 156-160
211. 296508 Ya gotta have HAART. Shafran SD. Conly JM CAN J INFECT DIS 1997 8 3 130-132
212. 296509 Human immunodeficiency virus protease inhibitors. Redshaw S, Thomas GJ EMERGING DRUGS 1997 2 127-154
213. 296510 To sequence or not to sequence? Gazzard B, Moyte G EXP OPIN INVEST DRUGS 1997 6 2 99-102
214. 296512 Design of novel, conformationally restricted HIV protease Inhibitors. Tung RD, Salituro FG, Rao GB, Baker CT, Deininger DD, Li B, Novak PM, Schairer WC, Court JJ. Porter M, Pazhanisamy S ANTIVIRAL RES 1997 34 2 A43
215. 296513 Piperazinyloxoquinoline derivatives, potent and selective inhibitors of HIV-1 transcription. Baba M, Okamoto M, Makino M, Kimura Y,
216. 296514 Drug resistance and its implications in the management of HIV Infection. Richman DD ANTIVIRAL THERAPY 1997 2 Suppl. 441-58
217. 296515 Novel antiretroviral therapies. ANTIVIRAL THERAPY'1997 2 Suppl. 1 20-23
218. 296516 Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. Schock HB, Gareky VM, Kuo LC J BIOL CHEM1996 271 50 31957-31963
219. 296517 HIV-proteinase inhibitors in the management of HIV-infection. Moyle GJ, Barton SE J ANTIMICROB CHEMOTHER 1996 386921-925
220. 296518 Vancouver: Optimism, but at a cost Churchill D, Pym A, Coker R INT J STDAIDS1996 7 6 385-387
221. 296519 Antiretroviral drug resistance: Mechanisms, pathogenesis, clinical significance. Richman DD ADV EXP MED BIOL 1996394 383-395
222. 296520 New initiatives in combination antiretroviral chemotherapy. Rooney JF. Warwick JC, Elkins MM, St. CLAIRMH, Barry DW ADV EXP MED BIOL 1996394 373-382
223. 296521 Phase I clinical trial with a novel protease inhibitor of HIV, KVX-478, in healthy male volunteers. Nishiyama M, Koishi M, Fujioka M, Hirala K, Yamamoto A, Suzuki H, Kurashima Y, Tei M, Uebaba K ANTIVIRAL RES 1996 301 A35
224. 296522 Rational approaches to resistance: using saquinavir. Boucher CAIDS1996101 S15-1 S19
225. 296524 Structure-based thermodynamic analysis of HIV-1 protease inhibitors. Bardi JS, Luque I, Freire E BIOCHEMISTRY 1997 36 22 6588-6596
226. 296527 AIDS trials ethics questioned. Cohen J SCIENCE 1997 276 5312520-523
227. 296528 Design and synthesis of novel conformationally restricted HIV protease inhibitors. Salituro FG, Baker CT, Court JT, Deininger DD, Kim EE, Liu B, Novak PM, Rao BG, Pazhanisamy S, Schairer WC, Tung RD ACS 1997 213 1 -3 MEDI307
228. 296529 British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Gazzard BG, Moyle GJ, Weber J, Johnson M, Bingham JS, Brettie R, Churchill D, Fisher M, Griffin G, Jefferies D, King E, et al LANCET 1997 349 9058 1086-1092
229. 296531 Saquinavir soft gel capsules studied in combination with viracepL AIDS PATIENT CARE STDS199711 2 98-99
230. 296533 Update on Invirase resistance. AIDS PATIENT CARE STDS 199711 135
231. 296534 Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV+ patients. McDowell JA, Sadler BM, Millard J, Nunnally P, Mustafa N ICAAC1997 37th Toronto
232. 13296535 Pharmacokinetic (PK) interaction between ketoconazole (KCZ) and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers. Polk RE, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WI, Crouch M, Gouldin W, Lou Y, Rawls C, Bye A ICAAC 1997 37th Toronto 12
233. 296536 Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P ICAAC 1997 37th Toronto 12
234. 296537 Pharmacokinetics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers. Sadler BM, Eron SJ, Wakeford J, Pagano G, Rawls C, McCrea J, Mazina K, Deutsch PJ ICAAC 1997 37th Toronto 12
235. 296539 Pharmacodynamics of 141W94 as determined by short term change in HIV RNA: Influence of viral isolate baseline EC50. Drusano J, Sadler WT, Millard M, Symonds C, Tisdale GL, Rawls BM, International Product Development Team (USA) ICAAC 1997 37th Toronto 4
236. 296541 In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Condra JH, Schleif WA, Blahy OM, et al NATURE 1995 374 6522 569-571
237. 296542 Structural analysis of the basis of viral resistance to VX-478. Kim EE, Dwyer MD, Thomson JA, Baker CT, Deininger DD, Tung RD, Navia MA, Rao BG ICAAC 1995 35th San Francisco 255
238. 296584 A molecular field-based similarity approach to pharmacophoric pattern recognition. Mestres J, Rohrer DC, Maggiora GM J MOLECULAR GRAPHICS MODELING 1997 15 2 114-121
239. 296587 Prospects for therapy of HIV-associated neurologic diseases. Sacktor N, McArthur J J NEUROVIROL 1997 3 2 89-101
240. 296589 An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94). Painter GR, St Clair MH, Demiranda P, Reynolds D, Ching S, Domsife R, Livingston DJ, Pazhanisamy S, Tung R AM SOC MICROBIOL 1995Washington DC 167
241. 296831 Biotechnology Quarterly. BancAmerica Robertson Stephens. June 25, 1998. Simon MJ, Miliotes GJ, Woolf NL, Freudenthal P, Silverman JB, Wright LJ, Silverman E, Perlin B ANALYST REPORT 1998
242. 296891 A new method for evaluation of combination chemotherapy regimens: Application to abacavir (1592U89 ABC) and aprenavir (141W94 - APV) Drusano GL, Preston SL, Bilello JA, Sadler B, Me Dowell J, Symonds W, Rogers M, Lafon S, Stein DS, Muir K, Bye A ICAAC 1998 38th San Diego Abs 5
243. 296893 Pharmacodynamics of penicillin in combination with azithromycin, cefepime, or vancomycin against penicillinresistant pneumococci, evaluated in the mouse peritonitis model. Knudsen J, Ostergaard C, Frimodt Moller N, Espersen F ICAAC 1998 38th San Diego Abs A6
244. 298965 Investigational anti-HIV drug Agenerase (amprenavir, formerly known as 141W94) to be made available through early access program. Glaxo Wellcome Inc PRESS RELEASE 1998September21
245. 299464 Phase III data on Agenerase, Vertex and Glaxo Wellcome's second-generation protease inhibitor, to be presented at a medical conference Vertex Pharmaceuticals Inc PRESS RELEASE 1998 September 24
246. 299504 Phase III results suggest potent antiviral activity for Vertex and Glaxo Wellcome's second-generation HIV protease inhibitor Agenerase Vertex Pharmaceutical Inc PRESS RELEASE 1998 September 27
247. 299659 Potential synergy shown between Agenerase and Ziagen Glaxo Wellcome pic PRESS RELEASE 1998 September 28
248. 301629 Glaxo Wellcome submits to PDA NDA for HIV protease inhibitor Agenerase (amprenavir). Glaxo Wellcome Inc PRESS RELEASE 1998 October 16
249. 301906 Vertex's partner Glaxo Wellcome submits application for market approval in Canada for HIV protease inhibitor Agenerase Vertex Pharmaceuticals Inc PRESS RELEASE 1998 October 20
250. 302157 Interscience Conference on Antimicrobial Agents and Chemotherapy: 38th Annual Meeting (Part VIII), Antiretroviral Chemotherapy and Respiratory Viruses, San Diego, CA, USA IDDB MEETING REPORT 1998 September 24-27
251. 302913 Glaxo Files NDA for first Vertex-designed compound B1OWORLD WEEK 1998 6 43 3
252. 303188 Vertex's Agenerase positive In phase III data B1OWORLD WEEK 1998 6 40 3
253. 303271 Vertex's partner Glaxo Wellcome submits regulatory application for novel HIV protease inhibitor, Agenerase, in the European Union. Vertex Pharmaceuticals Inc PRESS RELEASE 1998 November 2
254. 304360 Vertex and Glaxo Wellcome's Agenerase demonstrates promise In treatment-naive and treatment-experienced HIV patients Vertex Pharmaceuticals Inc PRESS RELEASE 1998 November 9
255. 306090 Drug development pipeline: agenerase, VX-710, VX-497, JNK Inhibitors, timcodar dimesylate, protease inhibitor Vertex, anti-hepatits C therapy Vertex Vertex Pharmaceuticals Inc COMPANY COMMUNICATION 1998 November 19 Mr Michael Partridge, Products Communication Manager, Vertex, supplied CD with details about VX-710 phase II trials for neoplasm, JNK inhibitor structure discovery, timcodar dimesylate phase II trials, caspase and HCV protease research at Vertex
256. 307580 The synthesis of indinavir and other clinically useful HIV-1 protease inhibitors. Askin D CURR OPIN DRUG DISCOVERY DEV1998 1 3 338-348
257. 310177 Looking down the drug pipeline Cadman J GMHC TREAT ISSUES 1998 12 3 Review of updates on the anti-HIV drug pipeline from the 5th Conference on Retroviruses and Opportunistic Infections, including detailed updates of the development of FTC, lodenosine, bis(POC)PMPA, AST-378, Immunex's GM-CSF and FP-21399.
258. 310262 Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV1. Kost, Cao, Vesanen, et al INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 1998 Feb 1-5 Chicago Abs
259. 310263 Abacavir + Amprenavir vs Nelfinavir WEB SITE 1998
260. 310951 Pharmaceutical and Biotechnological Bulletin Merrill Lynch ANALYST REPORT 1998 October 19
261. 311075 RP Scherer announces agreement with GlaxoWellcome R P Scherer Corp PRESS RELEASE 1999 January 8
262. 311130 Pharmaceutical & Biotechnology Bulletin Merrill Lynch ANALYST REPORT 1998 November 2
263. 311709 Glaxo Ziagen use may be defined by phase IV comparison trials FDC REPORTS PINK SHEET 1998 60 51 3
264. 312251 Vertex begins phase II clinical trial of VX-497 in psoriasis patients Vertex Pharmaceutical Inc PRESS RELEASE 1999 January 21
265. 312906 In-depth report - Glaxo Wellcome Merrill Lynch ANALYST REPORT 1998 November 16
266. 313089 Possibly unique resistance profile for the protease inhibitor Agenerase Glaxo Wellcome pic PRESS RELEASE 1999 February 1
267. 313212 Clinical trial results suggest Vertex and Glaxo Wellcome's novel HIV protease inhibitor Agenerase(TM) is potent, easy to take Vertex Pharmaceuticals Inc PRESS RELEASE 1999 February 2
268. 313406 Relenza, GS 4104 may make 1999 year of flu NMEs from antiviral division FDC REPORTS PINK SHEET 1999 61 227-28
269. 313469 Metabolic activity of Vertex's HIV protease inhibitor Agenerase appears markedly different from other protease inhibitors in laboratory Vertex Pharmaceuticals Inc PRESS RELEASE'1999 Februarys
270. 313588 In brief FDC REPORTS PINK SHEET 1999 61 2 40
271. 315582 Preliminary announcement of results for the year ended 31st December 1998 Glaxo Wellcome pic PRESS RELEASE 1999 February 18
272. 315725 Lehman Brothers - HIV/AIDS: do they have the right stu? ANALYST REPORT 1958 November 4
273. 315997 Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR J PHARM SCI 199887803-807 Detailed analysis of the interaction between amprenavir and cytochrome P450 systems.
274. 315999 Pharmacokinetics, excretion, and mass balance studies in dogs with 14C-141W94 (VX-478), an HIV-1 protease inhibitor. Studenberg SD, Dahl RR, Wooley JL N AM INT SOC STUDY OF XENOBIOTICS MEET 1996 San Diego
275. 316001 In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. Glynn SL, Yazdanian M J PHARM SC11998 87 306-310
276. 316013 Limited CD4+ renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Fleury S, et al NAT MED 19984794-801
277. 317541 Pharmaceutical, device and biotechnology bulletin ANALYST REPORT 1999 March 3
278. 317650 Paribas-European Equity Research ANALYST REPORT 1999 January 15.